Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of PTG-300 In Non-Transfusion Depenent (NTD) and Trasfusion-Dependent (TD) B-Thalassemia Subjects

NCT04054921 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.

NCT NCT04054921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04054921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of PTG-300 In Non-Transfusion Depenent (NTD) and Trasfusion-Dependent (TD) B-Thalassemia Subjects
Lead sponsor
Protagonist Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2019
Completion date
July 31, 2020
Enrollment
34 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ineffective erythropoiesis, β-thalassemia